Very Low LDL-C Levels Well Tolerated With Alirocumab

Share this content:
Very Low LDL-C Levels Well Tolerated With Alirocumab
Very Low LDL-C Levels Well Tolerated With Alirocumab

MONDAY, Jan. 30, 2017 (HealthDay News) -- For patients treated with alirocumab, very low low-density lipoprotein cholesterol (LDL-C) levels are not associated with increased treatment-emergent adverse event rates, according to research published in the Feb. 7 issue of the Journal of the American College of Cardiology.

Jennifer G. Robinson, M.D., M.P.H., from the University of Iowa in Iowa City, and colleagues examined the safety of alirocumab in patients with at least two consecutive LDL-C values <25 or <15 mg/dL. Pooled data from 14 trials were analyzed, representing 4,029 alirocumab and 2,114 control double-blind patient-years' exposure.

The researchers found that 25.1 and 9.4 percent of alirocumab-treated patients achieved two consecutive LDL-C values <25 mg/dL and <15 mg/dL, respectively. Patients with LDL-C <25 mg/dL versus ≥25 mg/dL had lower baseline LDL-C. Patients achieving LDL-C <25 mg/dL and <15 mg/dL had similar rates of adverse events (72.7 and 71.7 percent, respectively), compared with those who did not achieve LDL-C <25 mg/dL (76.6 percent). The three groups had similar neurological and neurocognitive events. The rate of cataracts was higher in patients with LDL-C <25 mg/dL versus ≥25 mg/dL in propensity score analysis (2.6 versus 0.8 percent, hazard ratio, 3.40). The incidence of cataracts, however, did not differ for pooled alirocumab and control groups.

"Low levels of LDL-C (<25 mg/dL) appear to be generally well tolerated over 18 months of alirocumab therapy," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Sanofi and Regeneron, both of which manufacture alirocumab and funded the analysis.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

ACOG: Shared Decision-Making Key to Breast Cancer Screening

ACOG: Shared Decision-Making Key to Breast Cancer Screening

Critically important for patient's value, preferences be factored into process, ACOG leader says

Three Lifestyle Interventions May Slow Cognitive Decline

Three Lifestyle Interventions May Slow Cognitive Decline

Cognitive training, management of hypertension, increased physical activity all help delay decline

CDC: Zika Can Be Found in Placental, Fetal Tissue at Birth

CDC: Zika Can Be Found in Placental, Fetal ...

Of 546 live births with possible maternal Zika virus, 11 percent proved positive

is free, fast, and customized just for you!

Already a member?

Sign In Now »